Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.

Alzheimers Dement (Amst) · 2022 · PMC9632865 · PMID 36348972

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

approached significanceno p-value reported

The solanezumab high dose did not significantly improve the treatment effect in any imaging or CSF biomarker outcomes compared to the low dose although the increase in CSF total Aβ42 approached significance.

also in 8,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.